Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRAZY GOOD NEWS TODAY . PLUS LOW FLOAT
MTST: effective Oct 8,2015 a one for 15 reverse split:
http://otce.finra.org/DLSymbolNameChanges
Things are looking good! I'm pleased so far
Moon shot for MTST today?
O/S: 27,630,052 (a/o May 21, 2015)
A/S: 150,000,000 (a/o February 24, 2015)
http://www.otcdynamics.com/$mtst-metastat-inc-promotional-campaign-starting-sep-2-2015-406-pm-cst/
Good luck
NEWS: Positive results of MenaCalc
http://content.stockpr.com/metastat/news/2015-09-02_MetaStat_Inc_Announces_Positive_Results_of_a_372.pdf
NEWS: Positive results of MenaCalc
http://content.stockpr.com/metastat/news/2015-09-02_MetaStat_Inc_Announces_Positive_Results_of_a_372.pdf
Form 4 just issued. CEO/president bought 10,000 more shares.
Added again at .24 today!
Getting everything at bargain basement prices lately! Loving it!
Nice value buy here at .26 today. Someone dumped 150k this morning.
Snagged some here, very pleased with my investment at this pps!
GLTA
Novel Metastatic Risk-Based Technology Could Transform Cancer Treatment Protocol
http://seekingalpha.com/article/3309435-novel-metastatic-risk-based-technology-could-transform-cancer-treatment-protocol
I sold and made some money on this not much but better than a loss.
I bough back in at .98 and just watched it drop like a rock off the edge of the Grand Canyon.
But as it is said you are already in so "Patience Grasshopper"
Cheers
Anyone still in this one? Glad I was smart and cut my losses while I still had money.
That is good. They do care for the investors.
Peter
I am hoping so :)
Excellent company to invest at this low PPS.
Peter
I meant Warren Lau not Winston
I had a great conversation with Mr. Winston Lau yesterday. I was kind of surprise to get an answer when I called.
we had a very good conversation which made me still believe in the technology that this company has created.
He did point me to the article on yahoo financial that indicated the future of this technology.
Therefore I am still holding and hoping that this technology will take off as it should.
Stock has been bouncing around all over lately. I'm still holding my shares. Don't have any free powder to buy more. I almost lost it when it hit in the 1.15's. We seem to bounce all over lately I don't get it. Just waiting for some good news to come out so this can pop.
Looks like dilution to me. Company is dumping shares to pay for something?
Just hanging out, not doing much. This one I have tucked away in my account for the long haul. I see big things happening later this year and into next year.
Their financials are on their website, you are free to examine it and report back, we would appreciate your analogy.
PR can say all they want. Do they have enough funding/investment in order to complete their diagnostic/therapeutic development? They might not even be able to see their products go public.
Thats why:
from the recent PR
" has products that have been shown to have promising results, and the company is expected to begin revenue generation in 2015, with an expected nationwide rollout of its service by 2018"
What makes you guys think that this stock is on the rise? All companies have news about themselves to make them look good.any specific reasons why you believe in this company so much?
Exactly. This is a $20+ once marketing is in full gear.
I see nothing but good things coming in the future for MTST.
Its a good time to do so. Next pr/news will catapult to $3+
+1. Thinking about buying another thousand shares in the low 1.40s.
yep, because it's not part of the yahoo message board and this ones very quiet is actually a good thing.
I'm not at all concern because this stock trades minimal. If it was a pump and dump the stock would have higher volumes and the share price would work itself down to a near bankrupt price (.01-.05). Also, very erratic price swings which tells me again, theres "not" a lot of share dumping going on.
nibble nibble!
hold
Just because people aren't posting on this board doesn't mean they aren't investing. I like that it's not being pumped up and bashed by hundreds of people.
read the news, that's why I'm holding long term here. Big things coming down the pipe for us.
Still here and holding. Sorry I dont post alot on ihubber.
Matty what makes you think MTST is a legit stockinvestment?
hey matt.
I like the look of this stock. I purchased some yesterday and will continue to nibble throughout the year. Very low volume has really caught my eye. Also the share holders on record (the major ones) are not dumping their shares in the mid $1.50's
Dilution should continue until revenue kicks in next year. that should be very expected as they have bills to pay.
I've did some research, don't really like their business address. It appears it's in an office of a past church or some type of christian library. I would assume it's just a local location among the board members and they only show 3 employee's.
This could play out to be very nice investment as long as they don't get carried away with dilution of stock.
average volume of 26k a day is unheard of with a price of $1.50 ish
good luck and if you see anything else in the way of news, share it, i will.
hold
Very low. Google what float means and then you'll understand. This has crazy swings because the volume is so low.
I'm adding more shares tomorrow. Once there drug hits this market this thing is going crazy.
float of 12.61 considered high or low?
Does this really have a float of 12.61 million? Yahoo finance has it sitting at that..
That's good to hear. How reliable do you think MTST is?
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
76
|
Created
|
02/18/14
|
Type
|
Free
|
Moderators |
MetaStat, Inc. (OTCQB: MTST) is a development stage life sciences company headquartered in Montclair, New Jersey. We are focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis - cancer that spreads from a primary tumor through the bloodstream to other areas of the body. Systemic metastasis is responsible for ~90% of all solid tumor cancer related deaths and as such, we believe that more effective treatment of metastatic disease and/or the prevention of systemic metastasis is needed to improve patient outcomes.
Our licensed proprietary platform technologies are based on the identification of a common pathway for the development of metastatic disease in solid epithelial-based tumors. These discoveries are the result of over 15 years of collaboration with four scientific/academic institutions that enabled us to understand the underlying biology and mechanisms of systemic metastasis. Central to these discoveries are i) the “MetaSite™,” the micro-anatomical site, or “window” in the blood vessels that metastatic cells squeeze through to enter the blood stream to begin their deadly spread, and ii) the pivotal role of the Mena protein and its isoforms in the metastatic cascade.
We are developing two function-based diagnostic product lines, MetaSite Breast™ and MenaCalc™. The MetaSite Breast™ test measures the process of systemic metastasis and is intended for early stage breast cancer patients. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. Both our MetaSite Breast™ and MenaCalc™ diagnostics are designed to accurately predict the probability of systemic metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of systemic metastasis who need aggressive therapy and by sparing patients with a low-risk of systemic metastasis from the harmful side effects and expense of chemotherapy.
Additionally, we are developing our MenaBloc™ therapeutic platform, with the goal of discovering inhibitors of key pathways that can be advanced as anti-cancer therapeutics in multiple epithelial-based tumor types.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |